

**Section of Hematology/Oncology  
Department of Medicine, Baylor College of Medicine  
(1 July 2017–30 June 2018)**



**Faculty**

Caroline E. Arber Barth, MD  
Malcolm K. Brenner, MD  
George Carrum, MD  
Gary C. Chamness, MD  
Chad Creighton, MD  
Matthew Ellis, MD  
Suzanne Fuqua, MD  
Svasti Haricharan, MD  
Bin He, MD  
Valentina Hoyos, MD  
Sao Jiralerspong, MD  
Aparna C. Jotwani, MD  
Mamta Kalidas, MD  
Rammurti Kamble, MD  
Salma Kaochar, PhD  
Meghashyam Kavuri, MD  
Weei-Chin Lin, MD PhD  
Fang- Tsy (Fannie) Lin, MD  
Premal Lulla, MD  
Maksim Mamonkin, MD  
Courtney N. Miller-Chism, MD  
Martha P. Mims, MD PhD  
Nicholas Mitsiades, MD PhD

Benjamin Musher, MD  
Julie Nangia, MD  
Charles K. Osborne, MD  
Carlos Ramos, MD  
Mothaffar F. Rimawi, MD  
Gustavo Rivero, MD  
Anita L. Sabichi, MD  
Yvonne Hsiao-Fan Sada, MD  
Rachel Schiff, MD  
Brandon G Smaglo, MD, FACP  
Iberia Romina Sosa, MD PhD  
Samer Srour, MD, MB, ChB, MS  
Sravanti P. Teegavarapu, MD  
Perumal Thiagarajan, MD  
Mark M. Udden, MD  
Juan Fernando Vera Valdes, MD  
Ayumi Watanabe, MD  
Zahida Yasin, MD  
Sarvari V. Yellapragada, MD  
Aihua E. Yen, MD  
Jun Zhang, MD

**Contents**

- A. Publications ..... 3
- B. Awards and Honors ..... 11
- C. Books and Book Chapters ..... 12
- D. Professional Organization/Association Offices Held ..... 12
- E. Editorial Board Memberships and Editorial Positions ..... 13
- F. Grants ..... 14
- G. Cash Rewards ..... 18

## **A. Publications**

1. Young M, Dahoun T, Sokrat B, **Arber C**, Chen KM, Bouvier M, Barth P. Computational design of orthogonal membrane receptor-effector switches for rewiring signaling pathways. *Proc Natl Acad Sci U S A*. 2018 Jul 3;115(27):7051-7056. doi: 10.1073/pnas.1718489115. Epub 2018 Jun 18. PMID:29915030
2. **Arber C**, Young M, **Barth P**. Reprogramming cellular functions with engineered membrane proteins. *Curr Opin Biotechnol*. 2017 Oct;47:92-101. doi: 10.1016/j.copbio.2017.06.009. Epub 2017 Jul 11. Review. PMID:28709113
3. **Brenner MK**. Onward and upward for immuno-oncology. *Chin Clin Oncol*. 2018 Apr;7(2):18. PMID:29764163
4. Yanir AD, Hanson IC, Shearer WT, Noroski LM, Forbes LR, Seeborg FO, Nicholas S, Chinn I, Orange JS, Rider NL, Leung KS, Naik S, **Carrum G**, Sasa G, Hegde M, Omer BA, Ahmed N, Allen CE, Khaled Y, Wu MF, Liu H, Gottschalk SM, Heslop HE, **Brenner MK**, Krance RA, Martinez CA. High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. *Biol Blood Marrow Transplant*. 2018 Apr 6. pii: S1083-8791(18)30163-0. PMID: 29630926
5. Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, **Carrum G**, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O'Connor O, Gee AP, **Brenner MK**, Heslop HE, Rooney CM. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. *J Clin Oncol*. 2018 Apr 10;36(11):1128-1139. PMID 29315015
6. Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, **Carrum G**, Sasa G, **Lulla P**, **Watanabe A**, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, **Brenner MK**, Rooney CM, Heslop HE, Leen AM, Omer B. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. *J Clin Oncol*. 2017 Nov 1;35(31):3547-3557. PMID:28783452
7. Kapke JT, Epperla N, Shah N, Richardson K, **Carrum G**, Hari PN, Pingali SR, Hamadani M, Karmali R, Fenske TS. Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. *Clin Lymphoma Myeloma Leuk*. 2017 Jul;17(7):408-414. PMID:28756899
8. Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, **Chamness GC**, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff R. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. *Clin Cancer Res*. 2017 Sep 1;23(17):5123-5134. PMID:28487443
9. Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, **Creighton CJ**, Wistuba II,

- Kurie JM. The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network..J Clin Invest. 2018 Jul 2;128(7):3198. doi: 10.1172/JCI122740. Epub 2018 Jul 2. No abstract available. PMID:30108197
10. Kundu ST, Grzeskowiak CL, Fradette JJ, Gibson LA, Rodriguez LB, **Creighton CJ**, Scott KL, Gibbons DL. TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins..Nat Commun. 2018 Jul 16;9(1):2731. PMID:30013069
  11. You R, DeMayo FJ, Liu J, Cho SN, Burt BM, **Creighton CJ**, Casal RF, Lazarus DR, Lu W, Tung HY, Yuan X, Hill-McAlester A, Kim M, Perusich S, Cornwell L, Rosen D, Song LZ, Paust S, Diehl G, Corry D, Kheradmand F. IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer. Cancer Immunol Res. 2018 Jun;6(6):645-657. PMID:29653981
  12. Haricharan S, Punturi N, Singh P, Holloway KR, Anurag M, Schmelz J, Schmidt C, Lei JT, Suman V, Hunt K, Olson JA Jr, Hoog J, Li S, Huang S, Edwards DP, Kavuri SM, Bainbridge MN, Ma CX, **Ellis MJ** .Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. Cancer discovery. 2017; 7(10):1168-1183. PMID:28801307
  13. Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, Katsonis P, Schmitt E, Chan DW, Li H, Mao S, Petrovic I, Creighton CJ, Gutierrez C, Dubrulle J, Stossi F, Tyner JW, Lichtarge O, Lin CY, Zhang B, Scott KL, Hilsenbeck SG, Sun J, Yu X, Osborne CK, Schiff R, Christensen JG, Shields DJ, Rimawi MF, **Ellis MJ**, Shaw CA, Lewis MT, Westbrook TF. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nature medicine. 2018; 24(4):505-511. PMID:29578538
  14. Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski MA, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Sanati S, Kawaler E, Wang X, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyö D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Reid Townsend R, Chen X, Carr SA, **Ellis MJ**, Ding L. Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nature communications. 2017; 8:14864. PMID: 28348404
  15. Baker A, Wyatt D, Bocchetta M, Li J, Filipovic A, Green A, Peiffer DS, **Fuqua S**, Miele L, Albain KS, Osipo C. Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival. Oncogene. 2018 May 10. doi: 10.1038/s41388-018-0251-y. [Epub ahead of print] PMID:29743588
  16. Zhang Z, Nikolai BC, Gates LA, Jung SY, Siwak EB, **He B**, Rice AP, O'Malley BW, Feng Q. Crosstalk between histone modifications indicates that inhibition of arginine methyltransferase CARM1 activity reverses HIV latency. Nucleic Acids Res. 2017 Sep 19;45(16):9348-9360 PMID: 28637181
  17. **Kaochar S, Mitsiades N**. A Novel Mechanism to Drive Castration-Resistant Prostate Cancer. Trends Endocrinol Metab. 2018 Jun;29(6):366-368. PMID:29605661

18. **Kaochar S**, Dong J, Torres M, Rajapakshe K, Nikolos F, Davis CM, Ehli EA, Coarfa C, **Mitsiades N**, Poulaki V. ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells. *Invest Ophthalmol Vis Sci.* 2018 Jan 1;59(1):132-143. PMID:29332125
19. Chinn IK, Eckstein OS, Peckham-Gregory EC, Goldberg BR, Forbes LR, Nicholas SK, Mace EM, Vogel TP, Abhyankar HA, Diaz MI, **Heslop HE**, Krance RA, Martinez CA, Nguyen TC, Bashir DA, Goldman JR, Stray-Pedersen A, Pedroza LA, Poli MC, Aldave-Becerra JC, McGhee SA, Al-Herz W, Chamdin A, Coban-Akdemir ZH, Jhangiani SN, Muzny DM, Cao TN, Hong DN, Gibbs RA, Lupski JR, Orange JS, McClain KL, Allen CE. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. *Blood.* 2018 Jul 5;132(1):89-100. PMID: 29632024
20. **Heslop HE, Brenner MK.** Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. *Mol Ther.* 2018 Jan 3;26(1):1-2. PMID:29273500
21. Ngwube A, Hanson IC, Orange J, Rider NL, Seeborg F, Shearer W, Noroski L, Nicholas S, Forbes L, Leung K, Sasa G, Naik S, Hegde M, Omer B, Ahmed N, Allen C, Gottschalk S, Wu MF, Liu H, Brenner M, **Heslop H**, Krance R, Martinez C. Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. *Biol Blood Marrow Transplant.* 2018 Mar;24(3):537-541. PMID: 29196075
22. Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, **Heslop HE**, Dotti G, Rooney CM, **Brenner MK.** CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. *Mol Ther.* 2017 Sep 6;25(9):2214-2224 PMID: 28602436
23. Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, **Brenner MK, Heslop HE**, Grossman R, Wels WS, Gottschalk S. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. *JAMA Oncol.* 2017 Aug 1;3(8):1094-1101. PMID: 28426845
24. Liu K, **Lin F-T**, Graves JD, Lee T-J and **Lin W-C.** Mutant p53 perturbs replication checkpoint response through TopBP1 and Treslin. *Proc. Natl. Acad. Sci., USA*, 2017; 114(19):E3766-E3775. PMID: 28439015.
25. **Lulla PD**, Hill LC, Ramos CA, Heslop HE. The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. *Clin Adv Hematol Oncol.* 2018 May;16(5):375-386.PMID:29851933
26. Bajgain P, Tawinwung S, D'Elia L, Sukumaran S, Watanabe N, Hoyos V, **Lulla P, Brenner MK**, Leen AM, Vera JF. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. *J Immunother Cancer.* 2018 May 10;6(1):34PMID:29747685
27. Tzannou I, Nicholas SK, **Lulla P**, Aguayo-Hiraldo PI, Misra A, Martinez CA, Machado AA, Orange JS, Piedra PA, Vera JF, Leen AM.Immunologic Profiling of Human

- Metapneumovirus for the Development of Targeted Immunotherapy. *J Infect Dis.* 2017 216(6):678-687. PMID:28934427
28. Aguayo-Hiraldo PI, Arasaratnam RJ, Tzannou I, Kuvalekar M, **Lulla P**, Naik S, Martinez CA, Piedra PA, Vera JF, Leen AM. Characterizing the Cellular Immune Response to Parainfluenza Virus 3. *J Infect Dis.* 2017 Jul 15;216(2):153-161. PMID:28472480
  29. **Mamonkin M**, Mukherjee M, Srinivasan M, Sharma S, Gomes-Silva D, Mo F, Krenciute G, Orange JS, Brenner MK. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. *Cancer Immunol Res.* 2018 Jan;6(1):47-58. PMID:29079655
  30. Dong J, Wong LJ, **Mims MP**. Mitochondrial inheritance and cancer. *Transl Res.* 2018 Jun 25. pii: S1931-5244(18)30100-2. doi: 10.1016/j.trsl.2018.06.004. [Epub ahead of print] Review. PMID: 30044960
  31. Flaig TW, Plets M, Hussain MHA, Agarwal **N**, **Mitsiades N**, Deshpande HA, Vaishampayan UN, Thompson IM Jr. Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. *JAMA Oncol.* 2017 Nov 9;3(11):e170231. PMID: 28358937
  32. Geng C, Kaochar S, Li M, Rajapakshe K, Fiskus W, Dong J, Foley C, Dong D, Zhang L, Kwon OJ, Shah S, Bolaki M, Xin L, Ittmann M, O'Malley BW, Coarfa C, **Mitsiades N**. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of cMYC oncoprotein. *Oncogene* 2017 Aug 17;36(33):4767-4777. PMID:28414305
  33. Date RC, Adams MK, Teh BS, Scheffler AC, **Musher BL**, Farach A, Weng CY A rare presentation of choroidal metastasis from primary esophageal adenocarcinoma successfully treated with intensity-modulated radiation therapy.. *Am J Ophthalmol Case Rep.* 2018 Apr 23;11:19-22. PMID: 30057967
  34. Balasubramanyam S, O'Donnell BP, **Musher BL**, Jhaveri PM, Ludwig MS Evaluating Treatment Patterns for Small Cell Carcinoma of the Colon Using the National Cancer Database (NCDB). *J Gastrointest Cancer.* 2018 Jan 22. doi:10.1007/s12029-018-0054-y. [Epub ahead of print] PMID:29354876
  35. Thyparampil PJ, Yen MT, Dhingra S, Shetlar DJ, Zarrin-Khameh N, **Musher BL**. Primary Neuroendocrine Tumor of the Orbit Presenting With Acute Proptosis. *Ophthalmic Plast Reconstr Surg.* 2018 Jan/Feb;34(1):e17-e19. PMID:28746252
  36. Barnes JA, Ellis ML, Hwang S, Emarine J, Merwin P, Salinas GD, **Musher BL**. Identification of Educational Gaps Among Oncologists Who Manage Patients with Pancreatic Cancer. *J Gastrointest Cancer.* 2017 Nov 27. doi: 10.1007/s12029-017-0033-8. [Epub ahead of print] PMID:29177608
  37. Freitas-Martinez A, Shapiro J, Goldfarb S, **Nangia J**, Jimenez JJ, Paus R, Lacouture ME. CME Part 1: Hair disorders in cancer patients. *J Am Acad Dermatol.* 2018 Apr 13. pii: S0190-9622(18)30529-2. PMID:29660422

38. **Nangia J.** Quality of Life Matters: It Is Time to Integrate Scalp Cooling in Routine Clinical Practice. *J Oncol Pract.* 2018 Mar;14(3):157-158. PMID:29529388
39. Gomes-Silva D, **Ramos CA.** Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line. *Biotechnol J.* 2018 Feb;13(2). doi: 10.1002/biot.201700097. Epub 2017 Oct 30. Review. PMID:28960810
40. **Ramos CA,** Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu M, Liu H, Grilley B, Bollard C, Chang BH, Rooney CM, Brenner MK, Heslop H, Dotti G, Savoldo B (2017) – Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. *The Journal of Clinical Investigation.* 127:3462-71 PMID:28805662
41. Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, **Ramos CA,** Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B (2017) – Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. *Journal of Clinical Oncology.* 35:3547-57. PMID: 28783452
42. Wapnir IL, Price KN, Anderson SJ, Robidoux A, Martín M, Nortier JWR, Paterson AHG, **Rimawi MF,** Láng I, Baena-Cañada JM, Thürlimann B, Mamounas EP, Geyer CE Jr, Gelber S, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi S; International Breast Cancer Study Group; NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group; Breast International Group. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. *J Clin Oncol.* 2018 Apr 10;36(11):1073-1079. PMID:29443653
43. Chang E, **Rivero G,** Patel NR, Chiao EY, Lai S, Bajaj K, Mbue JE, Yellapragada SV. HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab. *Clin Lymphoma Myeloma Leuk.* 2018 Feb;18(2):e143-e146. PMID:29342442
44. Chang E, **Sabichi AL,** Kramer JR, Hartman C, Royse KE, White DL, Patel NR, Richardson P, **Yellapragada SV,** Garcia JM, Chiao EY. Nivolumab Treatment for Cancers in the HIV-infected Population. *J Immunother.* 2018 Jul 16. doi: 10.1097/CJI.0000000000000240. [Epub ahead of print] PMID:30020193
45. **Sada YH,** Tran Cao HS, Chang GJ, Artinyan A, **Musher BL, Smaglo BG,** Massarweh NN. Prognostic value of neoadjuvant treatment response in locally advanced rectal cancer. *J Surg Res.* 2018 Jun;226:15-23 PMID: 29661280
46. Zou WY, El-Serag HB, **Sada YH,** Temple SL, Sansgiry S, Kanwal F, Davila JA. Determinants and Outcomes of Hospice Utilization Among Patients with Advance-Staged Hepatocellular Carcinoma in a Veteran Affairs Population. *Dig Dis Sci.* 2018 May;63(5):1173-1181. PMID:29508165
47. Tran Cao HS, Zhang Q, **Sada YH,** Chai C, Curley SA, Massarweh NN. The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts. *Cancer.* 2018 Jan 1;124(1):74-83. PMID:28841223

48. Tran Cao HS, Zhang Q, **Sada YH**, Silberfein EJ, Hsu C, Van Buren G 2nd, Chai C, Katz MHG, Fisher WE, Massarweh NN. Value of lymph node positivity in treatment planning for early stage pancreatic cancer. *Surgery*. 2017 Sep;162(3):557-567. PMID:28666686
49. Mason MC, Chang GJ, Petersen LA, **Sada YH**, Tran Cao HS, Chai C, Berger DH, Massarweh NN. National Quality Forum Colon Cancer Quality Metric Performance: How Are Hospitals Measuring Up? *Ann Surg*. 2017 Dec;266(6):1013-1020. PMID:27617852
50. Giuliano M, Shaikh A, Lo HC, Arpino G, De Placido S, Zhang XH, Cristofanilli M, **Schiff R**, Trivedi MV. Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. *Cancer Res*. 2018 Feb 15;78(4):845-852. PMID:29437766
51. Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino M, Hong T, Yang M, Liao Y, Chiang HC, Kaklamani VG, Jeselsohn R, Vadlamudi RK, Huang TH, Li R, De Angelis C, Fu X, Elizalde PV, **Schiff R**, Brown M, Xu K. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ER $\alpha$ -GREB1 Transcriptional Axis. *Cancer Res*. 2018 Feb 1;78(3):671-684. PMID:29212856
52. Ito K, Park SH, Katsyv I, Zhang W, De Angelis C, **Schiff R**, Irie HY. PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells. *NPJ Breast Cancer*. 2017 Nov 17;3:45. doi: 10.1038/s41523-017-0047-1. eCollection 2017. PMID:29167821
53. Deeken JF, Wang H, Hartley M, Cheema AK, **Smaglo B**, Hwang JJ, He AR, Weiner LM, Marshall JL, Giaccone G, Liu S, Luecht J, Spiegel JY, Pishvaian MJ. A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. *Cancer Chemother Pharmacol*. 2018 Mar;81(3):587-596. PMID:29392450
54. Quadri HS, **Smaglo BG**, Morales SJ, Phillips AC, Martin AD, Chalhoub WM, Haddad NG, Unger KR, Levy AD, Al-Refaie WB. Gastric Adenocarcinoma: A Multimodal Approach. *Front Surg*. 2017 Aug 3;4:42. doi: 10.3389/fsurg.2017.00042. eCollection 2017. Review. PMID:28824918
55. **Srou SA**, Lee HJ, Nomie K, Ye H, Chen W, Oriabure O, Romaguera J, Wang ML. Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma. *Br J Haematol*. 2018 May;181(4):561-564. dPMID:28369820
56. Jain P, Romaguera J, **Srou SA**, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang ML. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). *Clin Lymphoma Myeloma Leuk*. 2017 Jul;17(7):450-456. PMID:29785709
57. **Srou SA**, Machiorlatti M, Pierson NT, Bhutta UZ, Cherry M, Selby GB, Thompson DM, Vesely SK, Kurkjian CD. Impact of Health Care Insurance Status on Treatment Outcomes of Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk*. 2017 Jul;17(7):450-456. PMID:28624543
58. **Srou SA**, Li S, Popat UR, Qazilbash MH, Lozano-Cerrada S, Maadani F, Alousi A,



- Kebriaei P, Anderlini P, Nieto Y, Jones R, Shpall E, Champlin RE, Hosing C. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. *Br J Haematol*. 2017 Aug;178(4):561-570. PMID:28485023
59. Wu Y, Liu W, Zhou Y, Hilton T, Zhao Z, Liu W, Wang M, Yeon J, Houck K, **Thiagarajan P**, Zhang F, Shi FD, Wu X, Li M, Dong JF, Zhang J. Von Willebrand factor enhanced microvesicle-induced vascular leakage and coagulopathy in mice with traumatic brain injury. *Blood*. 2018 Jun 25. pii: blood-2018-03-841932. doi: 10.1182/blood-2018-03-841932. [Epub ahead of print] PMID:29941674
  60. Zhou Y, Cai W, Zhao Z, Hilton T, Wang M, Yeon J, Liu W, Zhang F, Shi FD, Wu X, **Thiagarajan P**, Li M, Zhang J, Dong JF. Lactadherin promotes microvesicle clearance to prevent coagulopathy and improves survival of severe TBI mice. *Blood*. 2018 Feb 1;131(5):563-572. PMID:29162596
  61. Bajgain P, Tawinwung S, D'Elia L, Sukumaran S, **Watanabe N, Hoyos V, Lulla P, Brenner MK**, Leen AM, Vera JF. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. *J Immunother Cancer*. 2018 May 10;6(1):34. PMID:29747685
  62. Kumar AJ, Kim S, Hemmer MT, Arora M, Spellman SR, Pidala JA, Couriel DR, Alousi AM, Aljurf MD, Cahn JY, Cairo MS, Cutler CS, Farhan S, Gergis U, Hale GA, Hashmi SK, Inamoto Y, **Kamble RT**, Kharfan-Dabaja MA, MacMillan ML, Marks DI, Nakasone H, Norkin M, Qayed M, Ringden O, Schouten HC, Schultz KR, Solh MM, Teshima T, Urbano-Ispizua A, Verdonck LF, Gale RP, Hamilton BK, Majhail NS, Loren AW. Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. *Blood Adv*. 2018 May 8;2(9):1022-1031. PMID:29739773
  63. Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, **Kamble RT**, Fanale MA. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. *Haematologica*. 2018 Apr 5. pii: haematol.2018.187617. PMID: 29622656
  64. Wood WA, Brazauskas R, Hu ZH, Abdel-Azim H, Ahmed IA, Aljurf M, Badawy S, Beitinjaneh A, George B, Buchbinder D, Cerny J, Dedeken L, Diaz MA, Freytes CO, Ganguly S, Gergis U, Almaguer DG, Gupta A, Hale G, Hashmi SK, Inamoto Y, **Kamble RT**, Adekola K, Kindwall-Keller T, Knight J, Kumar L, Kuwatsuka Y, Law J, Lazarus HM, LeMaistre C, Olsson RF, Pulsipher MA, Savani BN, Schultz KR, Saad AA, Seftel M, Seo S, Shea TC, Steinberg A, Sullivan K, Szwajcer D, Wirk B, Yared J, Yong A, Dalal J, Hahn T, Khera N, Bonfim C, Atsuta Y, Saber W. Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. *Biol Blood Marrow Transplant*. 2018 Mar 19. pii: S1083-8791(18)30129-0 PMID:29567340
  65. Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hematti P, Holmberg L,

- Inamoto Y, **Kamble RT**, Lehmann L, MacMillan MA, Mclver Z, Nishihori T, Norkin M, O'Brien T, Olsson RF, Reshef R, Saad A, Savani BN, Schouten HC, Seo S, Solh M, Verdonck L, Vij R, Wirk B, Yared J, Horowitz MM, Knight JM, Verneris MR. Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. *Bone Marrow Transplant*. 2018 Jul;53(7):932-937. PMID:29382954
66. Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf M, Chen AI, Choe H, Cohen J, Copelan E, Farooq U, Fenske TS, Freytes C, Gaballa S, Ganguly S, Jethava Y, **Kamble RT**, Kenkre VP, Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, Shah GL, Shah N, Solh M, Sureda A, William B, Cumpston A, Zelenetz AD, Link BK, Hamadani M. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. *Biol Blood Marrow Transplant*. 2018 Jun;24(6):1163-1171. PMID: 29242111
67. Qayed M, Wang T, Hemmer MT, Spellman S, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Aljurf M, Ayas M, Bitan M, Cairo M, Choi SW, Dandoy C, Delgado D, Gale RP, Hale G, Frangoul H, **Kamble RT**, Kharfan-Dabaja M, Lehman L, Levine J, MacMillan M, Marks DI, Nishihori T, Olsson RF, Hematti P, Ringden O, Saad A, Satwani P, Savani BN, Schultz KR, Seo S, Shenoy S, Waller EK, Yu L, Horowitz MM, Horan J. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. *Biol Blood Marrow Transplant*. 2018 Mar;24(3):521-528. PMID: 29155316
68. Arnold SD, Brazauskas R, He N, Li Y, Aplenc R, Jin Z, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, Majhail NS, Diaz MA, Freytes CO, Wood WA, Savani BN, **Kamble RT**, Parsons S, Ahmed I, Sullivan K, Beattie S, Dandoy C, Munker R, Marino S, Bitan M, Abdel-Azim H, Aljurf M, Olsson RF, Joshi S, Buchbinder D, Eckrich MJ, Hashmi S, Lazarus H, Marks DI, Steinberg A, Saad A, Gergis U, Krishnamurti L, Abraham A, Rangarajan HG, Walters M, Lipscomb J, Saber W, Satwani P. Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. *Haematologica*. 2017 Nov;102(11):1823-1832. PMID: 28818869
69. Gabriel M, Shaw BE, Brazauskas R, Chen M, Margolis DA, Sengelov H, Dahlberg A, Ahmed IA, Delgado D, Lazarus HM, Gibson B, Myers KC, **Kamble RT**, Abdel-Mageed A, Li CK, Flowers MED, Battiwalla M, Savani BN, Majhail N, Shaw PJ. Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR). *Biol Blood Marrow Transplant*. 2017 Aug;23(8):1320-1326 PMID:28411175
70. Vrooman LM, Millard HR, Brazauskas R, Majhail NS, Battiwalla M, Flowers ME, Savani BN, Akpek G, Aljurf M, Bajwa R, Baker KS, Beitinjaneh A, Bitan M, Buchbinder D, Chow E, Dandoy C, Dietz AC, Diller L, Gale RP, Hashmi SK, Hayashi RJ, Hematti P, **Kamble RT**, Kasow KA, Kletzel M, Lazarus HM, Malone AK, Marks DI, O'Brien TA, Olsson RF, Ringden O, Seo S, Steinberg A, Yu LC, Warwick A, Shaw B, Duncan C. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. *Biol Blood Marrow Transplant*. 2017 Aug;23(8):1327-1334. doi: 10.1016/j.bbmt.2017.04.017. Epub 2017 Apr 28. PMID: 28461213

## **B. Awards and Honors**

1. **Brenner:** European Society of Gene and Cell Therapy Outstanding Achievement Award<sup>l</sup>
2. **Ellis:** Forbes Physician Honor Roll December 2017
3. **Kaochar:** American Association of Cancer Research (AACR) Prostate 2017 Scholar-in-Training Award  
American Association of Cancer Research (AACR) Women in Cancer Research Award  
2018 Prostate Cancer Foundation Young Investigator Award
4. **Heslop:** President American Society of Gene and Cell Therapy
5. **Lulla:** ASH Scholar Award 2017
6. **Miller-Chism:** ASH Medical Educators Institute Scholar  
Baylor Oncology Fellowship; Best Clinic Experience Teaching of the Year, for Hematology Clinic; 2017/18
7. **Mims:** Houstonia Magazine Top Doctor  
Baylor Oncology Fellowship; Best Clinic Experience Teaching of the Year, for Hematology Clinic; 2017/18
8. **Musher:** "Top Doctor" Harris Health System  
Baylor Oncology Fellowship; Best Clinic Experience Teaching of the Year, for GI Oncology Clinic; 2017/18  
Houstonia Magazine Top Doctor
9. **Nangia:** Oncology Times Honorable Mention for Study Validating Safety and Efficacy of Scalp Cooling Technology
10. **Osborne:** 2018 AACR Distinguished Award for Extraordinary Scientific Achievement and Leadership in Breast Cancer Research.
11. **Rivero:** Center of Excellence in Healthy Equity, Training, and Research (COE) Junior Faculty Scholar 2017-2018 Cohort
12. **Sabichi:** Castle Connolly Top Doctors: 2017
13. **Sada:** Early Career Faculty Award for Excellence in Patient Care
14. **Smaglo:** Baylor Oncology Fellowship; Best Clinic Experience Teaching of the Year, for GI Oncology Clinic; 2017/18  
Duncan Cancer Center Early Phase Clinical Research Award
15. **Sosa:** That's The Way Player of the Month Award:  
Center of Excellence in Healthy Equity, Training, and Research (COE) Junior Faculty Scholar 2018-2019 Cohort
16. **Udden:** Chair, American Board of Internal Medicine Hematology Board  
Baylor Oncology Fellowship; Best Clinic Experience Teaching of the Year, for Hematology Clinic; 2017/18
17. **Yellapragada:** Star Faculty Award for Excellence in Patient Care  
Baylor Hematology Fellows Award for Teaching in Hematology

### **C. Books and Book Chapters**

1. **M. P. Mims** (2017) Thromboembolic Disease in Critical Care Obstetrics, Sixth Edition edited by Critical Care Obstetrics, 5th edition. Edited by M. Belfort, G. Saade, M. Foley, J. Phelan and G. Dildy. Blackwell Publishing Ltd.
2. R. Yates and **M. Mims** (2017) Testicular Cancer: Nonseminomatous Germ Cell Tumors: Early Stage, Late Stage in Handbook of Prostate Cancer and Other Genitourinary Malignancies. (2017) (editors: Teresa G Hayes, MD, PhD, Martha Mims, MD, PhD, Jennifer Taylor, MD). Demos Medical Publishing, New York, New York.
3. G. Kang and **M. Mims** (2017) Testicular Cancer: Controversies in Management in Handbook of Prostate Cancer and Other Genitourinary Malignancies. (2017) (editors: Teresa G Hayes, MD, PhD, Martha Mims, MD, PhD, Jennifer Taylor, MD). Demos Medical Publishing, New York, New York.
4. **R. Sosa**, and M.Udden (2017). Critical Care in Obstetrics. In M. Belfort, J. Phelan, G. Saade, M. Foley. Sickle Cell Disease and Pregnancy. (in press)
5. **S. A. Srour** and Muzaffar H. Qazilbash. Chronic Myeloid Leukemias in: "The Bethesda Handbook of Clinical Oncology" Editors: Jame Abraham and James L. Gulley. 5th edition. 2017. In Press.
6. **S. A. Srour** and Muzaffar H. Qazilbash. Chronic Myeloid Leukemias in: "The Bethesda Handbook of Clinical Oncology". Editors: Jame Abraham and James L. Gulley. 1<sup>ST</sup> edition. 2017. In Press.

### **D. Professional Organization/Association Offices Held**

1. **Heslop, H:**  
American Society of Gene and Cell therapy  
President  
American Society of Hematology  
Member, Nominating Committee  
Foundation for Accreditation of Cell Therapy  
President
2. **Miller-Chism, C:**  
American Society of Hematology  
Medical Medical Educators Institute  
Member, Question writing committee for ASH SAP
3. **Mims, M:**  
American Society of Hematology  
Member, ASH Committee on Training  
Chair, ASH Training Awards Committee  
Chair, ASH Research Training Award for Fellows Study Section  
Director K2R Program for ASH  
Member ASH Awards Committee;  
Member ASH Ambassador Program Faculty

- American Society of Clinical Oncology  
 Session Chair, Prostate Cancer 2018 Annual Meeting  
 American Society of Cancer Institutes Physician Clinical Leadership Initiative  
 Steering Committee Member  
 Baylor Principal Investigator for Southwest Oncology Group;  
 Member GU Oncology Committee of the Southwest Oncology group;  
 Member of SWOG Board of Governors;  
 Co-Chair Planning Committee for BCM/MDACC Comprehensive Board Review in  
 Hematology and Medical Oncology;
4. **Mitsiades, N:**  
 Southwest Oncology Group;  
 Member GU Oncology Committee
  5. **Musher, B:**  
 Southwest Oncology Group;  
 Member GI Oncology Committee
  6. **Rivero, G:**  
 Southwest Oncology Group;  
 Member Leukemia Committee
  7. **Sabichi, A:**  
 Southwest Oncology Group;  
 Member Lung Cancer Committee
  8. **Sada, Y:**  
 Southwest Oncology Group;  
 Member GI Oncology Committee
  9. **Smaglo, B:**  
 Southwest Oncology Group;  
 Member GI Oncology Committee
  - Sosa, R:**  
 American Society of Hematology  
 Member, Question writing committee for ASH SAP
  10. **Udden, M:**  
 American Board of Internal Medicine  
 Chair, Hematology Board
  11. **Yen, A:**  
 Southwest Oncology Group;  
 Member GU Oncology Committee

**E. Editorial Board Memberships and Editorial Positions**

**Brenner, M:** Editor and Chief Molecular Therapy  
**Heslop, H:** Editorial Board: Blood Journal, Hematology News, Cytotherapy  
 Deputy Editor: Molecular Therapy, Associate Editor: Blood  
**Mims, M:** Associate Editor: Translational Research  
**Mitsiades, N:** Editorial Board: Endocrine Related Cancer, International Journal of  
 Oncology, Journal of the Endocrine Society  
**Musher, B:** Clinical Gastroenterology and Hepatology reviewer (ad hoc); New England  
 Journal of Medicine reviewer (ad hoc)  
**Osborne, CK:** Editorial Board: Breast Cancer Research, Cancer Research  
**Rivero, G:** Associate Editor: Blood Research and Disorders Journal  
**Sabichi, A:** Editorial Board, The Scientific World Journal; Editorial Board, New Journal of

**E. Grants**

1. **Arber Barth, C:** Genetically Engineered Virus-Specific T Cells To Prevent And Treat Relapse And Infection After Allogeneic Hematopoietic Stem Cell Transplantation Leukemia & Lymphoma Society 6490-16 (10/1/2015 - 9/30/2018)
2. **Brenner, M** Engineering T Cells To Ensure Specificity For Tumor Cells And Their Environment Cancer Prevention & Research Institute Of Texas (CPRIT) RP160345 (9/15/2016 - 2/28/2019)
3. **Brenner, M:** Amendment/NCE - To Extend Agreement- Followup For Lokon (Sample Analysis For The Clinical Trial) Lokon Pharma Ab (10/15/2017 - 10/14/2018)
4. **Carrum, G:** A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase Iii Trial Of The Flt3 Inhibitor Gilteritinib Administered As Maintenance Therapy Following Allogeneic Transplant For Patients With Flt3-Itd Aml Bmt Ctn Protocol #1506/Astellas Astellas Pharma Global Development , Inc. Protocol Rider 1501 (Amend1) (12/7/2017 - 8/31/2018)
5. **Chamness, G:** NRG Oncology Biospecimen Bank National Institutes Of Health (NIH) U24-CA196067-04 (4/1/2015 - 3/31/2019)
6. **Chamness, G:** A Phase II Clinical Trial Platform Of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) In Rectal Cancer (The "G1002 Project" National Surgical Adjuvant Breast And Bowel Project (NSABP) NRG-G1002 (11/1/2016 - 10/31/2018)
7. **Chamness, G:** NCE - NSABP B47 Sub Study NIH: National Institutes Of Health NONE-NSABP (NCE) (8/1/2017 - 12/31/2017)
8. **Creighton, C:** Mira / Core 2 - Integrated Analysis Of The Lung Cancer Microenvironment Cancer Prevention & Research Institute Of Texas (CPRIT) RP120713-C2 Year 6 (Year 1: 8/31/2017 - 8/31/2018)
9. **Creighton, C:** BC150251: A Novel Preclinical Model Of Dormant Metastatic ER+ Breast Cancer Department Of Defense W81XWH-16-1-0044 (2/1/2018 - 1/31/2019)
10. **Creighton, C:** Regulation Of Lung Cancer Metastasis By Zeb1 National Cancer Institute (NCI) R01-CA181184-04 (7/1/2014 - 6/30/2018)
11. **Ellis, M:** Alternate Trial: A Neoadjuvant Biomarker Approach For Estrogen Receptor Positive Breast Cancer Breast Cancer Research Foundation BCRF-16-102 (10/1/2014 - 9/30/2018) \$11,544
12. **Ellis, M:** Investigation Of The Genomics And Biology Of Metastasis Using Patient-Derived-Xenografts (PDX) Breast Cancer Research Foundation ELFF-16-003 (9/1/2014 - 5/31/2018)
13. **Ellis, M:** 16-Month NCE BCRF PDX Founders Fund - Investigation Of The Genomics And Biology Of Metastasis Using Patient-Derived-Xenografts (PDX) Breast Cancer Research Foundation ELFF-16-003 - NCE (amend5 MSK) (6/1/2018 - 6/30/2019)
14. **Ellis, M:** BR003-A Randomized Phase III Trial Of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed By Weekly Paclitaxel With Or Without Carboplatin In Node-Positive Or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer Breast Cancer Research Foundation BCRF-16-042 (10/1/2014 - 9/30/2018)
15. **Ellis, M:** Established Investigator Recruit - Accelerating Breast Cancer Translational Medicine Through Genomics And Proteomics Cancer Prevention & Research Institute Of Texas (CPRIT) RR140033 (6/1/2014 - 5/31/2019)
16. **Ellis, M:** Integrated Translational Genoproteomics Center At Washington University (Wu-18-361) National Institutes Of Health (NIH) U10-CA180860 (3/1/2014 - 2/28/2019)

17. **Ellis, M:** NRG Oncology Network Group Operations Center National Institutes Of Health (NIH) U10-CA180868-05 (3/1/2014 - 2/28/2019)
18. **Ellis, M:** Microscaled Proteogenomics For Cancer Clinical Trials (Cptac) National Institutes Of Health (NIH) U01-CA214125 -02 (Amend2 BI) (6/1/2017 - 5/31/2022)
19. **Ellis, M:** Somatic Mutation And Recurrence Risk For Early Stage Estrogen Receptor Positive Breast Cancer Susan G Komen Breast Cancer Foundation SAC170059 (YR2-WUSTL) (2/20/2017 - 2/19/2019)
20. **Ellis, M:** Direct Regulation Of Estrogen Receptor Transcriptional Activity By Nf1 United States Army Medical Research & Materiel Command ( Department Of Defense ) W81XWH-16-1-0539 (9/30/2016 - 9/29/2019)
22. **Fuqua, S:** Role Of Esr1 Mutations In Breast Cancer Progression Breast Cancer Research Foundation BCRF-16-056 (10/1/2014 - 9/30/2018)
23. **Fuqua, S:** Mira/Project 2: Characterization Of Nuclear Receptor And Co-Regulator Expression And Function In Breast Cancers Cancer Prevention & Research Institute Of Texas (CPRIT) RP120732-P2 Attach F2 (8/31/2012 - 8/30/2018)
24. **Fuqua, S:** Year 4 NCE: Effects Of Hormonal Therapy On Subclonal Evolution Of Breast Tumors With Esr1 Mutations Cancer Prevention & Research Institute Of Texas (CPRIT) RP150440 (3/1/2015 - 8/31/2018)
25. **Fuqua, S:** Integration Of Predictive Biomarkers Of Hormone Resistance In Breast Cancer National Cancer Institute (NCI) R01-CA072038-19 (9/1/1996 - 8/31/2019)
26. **Fuqua, S:** Mechanisms Of Ar-Er Collaboration In Hormone Resistance And Metastasis Of Breast Cancer National Institutes Of Health (NIH) R01-CA207270-02 (3/1/2017 - 2/28/2022)
27. **Haricharan, S:** BC170276 Mismatch Repair Loss Renders Er+/Her2- Breast Cancer Susceptible To Her2/3 Inhibition United States Army Medical Research & Materiel Command ( Department Of Defense) W81XWH-18-1-0034 (3/1/2018 - 2/28/2019)
28. **He, B:** Role Of Gata2 In Prostate Cancer Development American Cancer Society RSG-13-061-01 (1/1/2015 - 12/31/2018)
29. **Heslop, H:** Enhancing T Cell Therapy of Cancer National Institutes Of Health (NIH) 5P01CA094237 (2/1/16-1/31/19)
30. **Heslop, H:** Cancer Cell and Gene Therapy Program (CCSG) National Institutes Of Health (NIH) 5P30CA125123 (7/1/2007-6/30/19)
31. **Heslop, H:** Translational Research In Lymphoma (SPORE) National Institutes Of Health (NIH) P50-CA126752 (4/1/2007-8/31/2022)
32. **Heslop, H:** Training in Cell and Gene Therapy National Institutes of Health (NIH) 5T32HL092332 (7/1/2003-7/31/2019)
33. **Hoyos, V:** Recruitment Of First-Time, Tenure Track Faculty Member–Dr. Valentina Hoyos Velez (RFT) Cancer Prevention & Research Institute Of Texas (CPRIT) RR170024 (8/31/2017 - 8/30/2022)
34. **Jiralerspong, S:** NCE 2- Metformin For The Treatment Of Breast Ductal Carcinoma In Situ (DCIS) Susan G Komen Breast Cancer Foundation CCR13263802 (8/27/2017 - 8/26/2018)
35. **Kavuri, M:** BC170466: Targeting Ddr1 Aberrations In Metastatic Er+ Breast Cancer Department Of Defense Congressionally Directed Medical Research Programs W81XWH-18-1-0040 (2/15/2018 - 2/14/2019)
36. **Kavuri, M:** Kinome Analysis To Rationalize Targeting HER2 And DDR1 Breast Cancer Mutations Susan G Komen Breast Cancer Foundation CCR16380599 (9/15/2016 - 9/14/2019)
37. **Kavuri, M:** BC170276P1 Mismatch Repair Loss Renders Er+/Her2- Breast Cancer Susceptible To Her2/3 Inhibition United States Army Medical Research & Materiel

Command ( Department Of Defense ) W81XWH-18-1-0035 (3/1/2018 - 2/28/2021)

38. **Lin, W:** NCE: BC133678 Targeting A Convergent Point Of Multiple Oncogenic Pathways In Breast Cancer, A New Paradigm For Targeted Therapy Department Of Defense Congressionally Directed Medical Research Programs W81XWH-14-1-0339 (9/30/2017 - 9/29/2018)
39. **Lin, W:** The ATM/E2F1 Pathway In Dna Damage And Growth Control National Institutes Of Health (NIH) R01-CA100857-14 (3/1/2003 - 2/28/2020)
40. **Lin, W:** MPI-Novel Therapeutics For Targeting Checkpoint Dysfunction In Cancer National Institutes Of Health (NIH) R01-CA203824-02 (12/1/2016 - 11/30/2021)
41. **Lin, W:** New Mechanisms Of Breast Cancer Metastasis And Loss Of Estrogen Receptor Driven By 14-3-3 (NIH): National Institutes Of Health R21-CA198041-02 (6/1/2016 - 5/31/2019)
- 42.. **Lin, W:** BCM Oncology Scholars Training Program The National Institutes Of Health T32-CA174647-04 (8/1/2014 - 7/31/2019)
43. **Lulla, P:** T Cell Therapy For AML American Society For Blood & Marrow TR (7/1/2016 - 6/30/2019)
44. **Lulla, P:** Safety And Efficacy Of Adoptively Transferred Multitaa Specific T Cells To Patients With Multiple Myeloma American Society Of Hematology (7/1/2017 - 6/30/20120)
45. **Lulla, P:** Adoptively Transferred Multitaa-Specific T Cells As Treatment Or Prevention Of Aml Relapse Post-Allogeneic Stem Cell Transplant Leukemia Texas, Inc. (7/1/2016 - 6/30/2018)
46. **Mamonkin, M:** Increasing Safety Of Cd5 Car For The Treatment Of T Cell Malignancies American Society Of Hematology (7/1/2016 - 6/30/2019)
47. **Mitsiades, N:** Ubiquitination-Based Control Of Transcriptional Activity In Prostate Cancer American Cancer Society RSG-14-218-01-TBG (1/1/2015 - 12/31/2018)
48. **Mitsiades, N:** PC160445: A First-In-Field Approach To Target A Previously Undruggable Oncogene Family In Prostate Cancer Department Of Defense Congressionally Directed Medical Research Programs W81XWH-17-1-0298 (7/1/2017- 6/30/2020)
49. **Mitsiades, N:** Developing Spop Inhibitors Diana Helis Henry Medical Research Foundation Cancer Program H-2017 (4/1/2017 - 3/31/2019)
50. **Mitsiades, N:** Regulation Of Uveal Melanoma Cell Fate By Mitf Via The PKC Pathway National Cancer Institute (NCI) R01-CA193321-03 (8/1/2015 - 7/31/2020)
51. **Mitsiades, N:** A Novel Therapeutic Target For Prostate Cancer Sidney Kimmel Foundation For Cancer R SKF-15-053 (7/1/2015 - 6/30/2018)
52. **Nangia, J:** Breast Cancer Research And Education Program Astrazeneca (9/7/2017 - 9/6/2018)
53. **Nangia, J:** Nanostring Educational Grant Nanostring Technologies NanoString (8/1/2017 - 7/31/2018)
54. **Nangia, J:** Educational Retreat Pfizer, Inc (9/1/2016 - 8/31/2018)
55. **Nangia, J:** 2018-2019: Facilitating Breast Cancer Prevention And Treatment In Underserved And Minority Women Susan G Komen - Houston Affiliate CGA-2018-TX105-BAYL46-00030 (4/1/2018 - 3/31/2019)
56. **Osborne, C K:** Baylor College Of Medicine Cancer Center National Cancer Institute (NCI) P30-CA125123-11 (7/1/2007 - 6/30/2020)



57. **Osborne, C** KP30 Administrative Supplement For P30 Cancer Center Support Grants To Support Research In Canine Immunotherapy Via Collaboration Of Nci-Designated Cancer Centers And Veterinary Medical Colleges (Identifying Neo-Epitopes For Cd8+ T Cells In Dog Tumors) National Cancer Institute (NCI) P30-CA125123-10S4 (7/1/2017 - 12/31/2018)
58. **Osborne, C K:** RFA: NCI Moonshot Initiative: Administrative Supplements For The P30 Cancer Center Support Grant To Develop Tobacco Cessation Treatment Capacity And Infrastructure For Cancer Patients National Cancer Institute (Nci) P30-CA125123 (7/1/2017 - 6/30/2018)
59. **Osborne, C K:** 11S2 Underrepresented High School And Undergraduate Student Research Experiences (Cure) National Cancer Institute (NCI) P30-CA125123-11S2 (7/1/2017 - 6/30/2018)
60. **Osborne, C K:** 11S1 Administrative Supplement To Strengthen NCI-Supported Community Outreach Capacity Through Community Health Educators (CHES) Of The National Outreach Network (NON) National Cancer Institute (NCI) P30-CA125123-11S1 (7/1/2017 - 6/30/2018)
61. **Osborne, C K:** To Fund Year 11 Administrative Supplement Not Affiliated With The Experimental Therapeutic Clinical Trials Network (Etctn) To Support Participation In The Etctn Prior Year: 10 ( Brain 23664-S37) National Cancer Institute (NCI) P30-CA125123 (7/1/2017 - 6/30/2018)
62. **Osborne, C K:** 11S3 : Improving Diagnostic Accuracy And Supportive Care For Children With Burkitt Lymphoma: Laying A Foundation For Treatment Trials In Sub-Saharan Africa National Cancer Institute (NCI) P50-CA125123 (7/1/2017 - 6/30/2018)
63. **Osborne, C K:** Translational Research In Breast Cancer (SPORE) National Institutes Of Health (NIH) P50-CA186784-04 (9/1/2014 - 8/31/2019)
64. **Osborne, C K:** Amendment 2 To The Ventana Collaborative Research Agreement Ventana Medical Systems, Inc (1/24/2018 - 6/30/2018)
65. **Ramos, C:** Amendment: HPV 16/18 E6/E7-Specific T Cells For Treatment Of HPV-Associated Cancers Tessa Therapeutics Pte. Ltd. (5/1/2018 - 4/30/2019)
66. **Rimawi, M:** Pink For Life- Expanding And Improving Breast Cancer Care And Prevention In Minority And Economically Disadvantaged Women Avon Foundation 05-2017-002 (7/1/2017 - 6/30/2018)
67. **Rimawi, M:** NCE TBCRC 2017: Translational Breast Cancer Research Consortium Infrastructure Support Task Order: BCRF Original Po 2000010764 Breast Cancer Research Foundation (7/1/2017 - 6/30/2018)
68. **Rimawi, M:** BC161327: A New Paradigm For De-Escalation Of Treatment In Her2 Positive Breast Cancer: Revolutionizing Care With More Effective And Less Toxic Therapy. Department Of Defense Congressionally Directed Medical Research Programs W81XWH-17-1-0579 (9/15/2017 - 9/14/2020)
69. **Rimawi, M:** Biological Samples For: A Phase II Randomized Study Evaluating The Biological And Clinical Effects Of The Combination Of Palbociclib With Letrozole As Neoadjuvant Therapy In Women With Estrogen Receptor-Positive Primary Breast Cancer” (The “Fb-11 Study) Pfizer, Inc Service Agreement (10/20/2017 - 10/19/2019)
70. **Rimawi, M:** TBCRC 2017: Translational Breast Cancer Research Consortium Infrastructure Support Task Order: Susan G Komen Breast Cancer Foundation (7/1/2017 - 6/30/2018)
71. **Schiff, R:** 2017-2018: Mechanisms Of Resistance To HER2 And ER-Targeted Therapies And Novel Therapeutic Strategies Breast Cancer Research Foundation BCRF-17-143 (10/1/2017 - 9/30/2018)

72. **Schiff, R:** Pre-Clinical Investigation Of Brd4 Inhibitors In Hormone-Insensitive Er+ Breast Cancer Gilead Sciences, Inc. (12/15/2017 - 2/17/2019)
73. **Schiff, R:** NIK As Attractive Drug Target For Intractable Breast Cancer” (5R01CA18136) National Institutes Of Health (NIH) R01-CA181368-04 (9/1/2014 - 8/31/2018)
74. **Schiff, R:** Evaluate The Therapeutic Efficacy Of Neratinib In Combination With Trastuzumab For HER2-Positive Breast Cancer Puma Biotechnology Inc SRA (1/1/2018 - 12/31/2019)
75. **Schiff, R:** BC133693P1: Targeting Gpr110 In Her2-Overexpressing Breast Cancer United States Army Medical Research & Materiel Command ( Department Of Defense ) W81XWH-14-1-0341 (9/30/2014 - 9/29/2018)
76. **Schiff, R:** Harvey Amendment BC133693P1: Targeting GPR110 In HER2-Overexpressing Breast Cancer United States Army Medical Research & Materiel Command (Department Of Defense ) W81XWH-14-1-0431 (4/26/2014 - 9/30/2018)
77. **Schiff, R:** BC161327P1 : A New Paradigm For De-Escalation Of Treatment In HER2 Positive Breast Cancer: Revolutionizing Care With More Effective And Less Toxic Therapy. United States Army Medical Research & Materiel Command ( Department Of Defense ) W81XWH-17-1-0580 (9/15/2017 - 9/14/2020) \$692,420
78. **Sosa, I R:** Resveratrol In Metabolic Syndrome: Effect On Platelet Hyper-Reactivity And Hdl Lipid Peroxidation American Heart Association Inc 13FTF174000111 (7/1/2014 - 6/30/2018)
79. **Suzuki, M:** Combining Ad Gene Therapy With Car Ad-Specific T-Cell Therapy For HNSCC Concern Foundation (7/1/2016 - 6/30/2018)
80. **Suzuki, M:** Amendment - Combinatorial Treatment With Armed Oncolytic Ad Gene Therapy And Car T-Cell Therapy For Squamous Cell Carcinoma Of The Head And Neck (HNSCC) Tessa Therapeutics Pte. Ltd. SRA Amendment 1 (1/1/2018 - 12/31/2018) \$100,000
81. **Vera Valdes, J::** Engineered T Cell Therapy For Advanced Prostate Cancer American Cancer Society MRSG-14-19701-LIB (1/1/2015 - 12/31/2018)
82. **Watanabe, N:** Cook Regentec LLS SRA Cook Regentec Testing Agreement (9/21/2017 - 9/20/2018)

## **G. Cash Awards**

1. **Carrum, G:** Astellas Pharma Global Development , Inc. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial To Evaluate The Protective Efficacy And Safety Of A Therapeutic Vaccine, Asp0113, In Cytomegalovirus (Cmv)-Seropositive Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
2. **Carrum, G:** National Institutes Of Health (NIH) U10HL069294 Prospective Multi-Center Cohort For The Evaluation Of Biomarkers Predicting Risk Of Complications And Mortality Following Allogeneic HCT, BMT CTN 1202
3. **Carrum, G:** NIH: National Institutes Of Health U10CA180888 \*\*Swog Purchase Service Agreement: Subaccount For Participation In Nci Nctn Clinical Trials\*\* CTSU - H-39725 BMT CTN 1201 A051301 Alliance DLBC - A Randomized Double-Blind Phase Iii Study Of Ibrutinib During And Following Autologous Stem Cell Transplantation Versus Placebo In Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Of The Activated B-Cell Subtype
4. **Cnamness, G:** NIH: National Institutes Of Health NSABP B47 Sub Study
5. **Heslop, H:** Cell Medica, Ltd Citadel-A Phase 2 Open Label Study To Investigate The Efficacy Of Autologous Ebv-Specific T-Cells For The Treatment Of Patients With

Aggressive Extranodal Nk/T Cell Lymphoma (ENKTCL), CM-2013-01

6. **Heslop, H:** Cell Medica, Ltd Prevale- Phase I Study Combining Nivolumab With Epstein Barr Virus Specific T Cells (Eb-Vsts) In Relapsed/Refractory Ebv Positive Lymphoma Patients
7. **Kamble, R:** National Institutes Of Health (NIH) 2U10HL069294 A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant To Hypomethylating Therapy Or Best Supportive Care In Patients Aged 50-75 With Intermediate-2 And High Risk Myelodysplastic Syndrome, BMT CTN 1102
8. **Lulla, P:** National Institutes Of Health (NIH) U01HL128566-01 Year 3 Amendment - BMT CTN 1503: Hematopoietic Stem Cell Transplantation For Young Adults With Sickle Cell Disease
9. **Lulla, P:** Tessa Therapeutics Pte. Ltd. A Multicentre, Randomized, Open-Label, Phase Iii Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma Patients
10. **Mims, M:** Aveo Pharmaceuticals A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study To Compare Tivozanib Hydrochloride To Sorafenib In Subjects With Refractory Advanced Renal Cell Carcinoma
11. **Mims, M:** Bristol-Myers Squibb 1 Ca204006: A Phase 3, Randomized, Open Label Trial Of Lenalidomide/Dexamethasone With Or Without Elotuzumab In Subjects With Previously Untreated Multiple Myeloma
12. **Mims, M:** Celgene Corporation Cc-5013-Nhl-008: A Phase 3B Randomized Study Of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed By Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance In Subjects With Relapsed/Refractory Follicular, Marginal Zone Or Mantle Cell Lymphoma
13. **Mims, M:** Imclone Systems Incorporated Cp02-0452: Randomized Phase Iii Study Of Docetaxel Or Pemetrexed With Or Without Cetuximab In Patients With Recurrent Or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy
14. **Mims, M:** Novartis Pharmaceuticals Corp 1 Rad001N2301: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase Iii Study Of Rad001 Adjuvant Therapy In Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Of Rad001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-Line Rituximab-Chemotherapy
15. **Mims, M:** Prostate Cancer Clinical Trials Consortium, Llc Prostate Cancer Outcomes: An International Registry To Improve outcomes In Men With Advanced Prostate Cancer (Ironman)
16. **Musher, B:** Aduro Biotech, Inc. A Phase 2, Open-Label Evaluation Of Crs-207 And Pembrolizumab In Adults With Recurrent Or Metastatic Gastric, Gastroesophageal Junction, Or Esophageal Adenocarcinomas
17. **Musher, B:** Boston Biomedical, Inc Canstem111P: A Phase III Study Of Bbi-608 Plus Nab-Paclitaxel With Gemcitabine In Adult Patients With Metastatic Pancreatic Adenocarcinoma.
18. **Musher, B:** Celgene Corporation Abi-007-Panc-003 A Phase 3, Multicenter, Open-Label, Randomized Study Of Nab®-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone As Adjuvant Therapy In Subjects With Surgically Resected Pancreatic Adenocarcinoma
19. **Musher, B:** Eli Lilly And Company A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Of Capecitabine And Cisplatin With Or Without Ramucirumab As First-Line Therapy In Patients With Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma (Rainfall)

20. **Musher, B:** Halozyme Therapeutics A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of Pegylated Recombinant Human Hyaluronidase (Pegph20) In Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel And Gemcitabine In Subjects With Hyaluronan-High Stage Iv Previously Untreated Pancreatic Ductal Adenocarcinoma
21. **Musher, B:** Lokon Pharma Ab Phase I/IIa Trial Evaluating Safety Of Load703 An Armed Oncolytic Adenovirus For Pancreatic Cancer
22. **Musher, B:** Merck Sharpe & Dohme Corp. A Phase III Study Of Pembrolizumab (Mk-3475) Vs. Chemotherapy In Microsatellite Instability-High (Msi-H) Or Mismatch Repair Deficient (Dmmr) Stage Iv Colorectal Carcinoma (Keynote-177)
23. **Musher, B:** Newlink Genetics Corporation 1 Nlg-0505: A Phase III Study Of Folfirinox With Or Without Hyperacute-Pancreas (Algenpantucel-L) Immunotherapy In Subjects With Borderline Resectable Or Locally Advanced Unresectable Pancreatic Cancer
24. **Nangia, J:** Calithera Biosciences H-41704: A Multicenter Phase 2 Study Of The Glutaminase Inhibitor Cb-839 In Combination With Paclitaxel In Patients With Advanced Triple Negative Breast Cancer (Tnbc) Including Patients Of African Ancestry And Non-African Ancestry
25. **Nangia, J:** Celldex Therapeutics, Inc. A Randomized Multicenter Pivotal Study Of Cdx-011 (Cr011-Vcmmae) In Patients With Metastatic, Gpnmb Over-Expressing, Triple-Negative Breast Cancer
26. **Nangia, J:** Paxman Coolers Limited Scalp Cooling For Alopecia Prevention (Scalp)
27. **Nangia, J:** Tesaro, Inc. H-42264: 3000-01-005 An Open-Label, Single-Arm Pilot Study Evaluating The Antitumor Activity And Safety Of Niraparib As Neoadjuvant Treatment In Localized, Her2- Negative, Brca-Mutant Breast Cancer Patients
28. **Ramos, C:** Viracyte LLC A Phase I Study Using Most Closely Hla-Matched Adenovirus-Specific T-Lymphocytes For The Treatment Of Adenovirus Infections Post Allogeneic Stem Cell Transplant (Viralym-A)
29. **Rimawi, M:** Abbvie Inc H-42427: An Open Label Study Of Sc-005 In Subjects With Triple Negative Breast Cancer (Tnbc)
30. **Rimawi, M:** Amgen, Inc. "A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study Of Denosumab As Adjuvant Treatment For Women With Early-Stage Breast Cancer At High Risk Of Recurrence (D-Care).
31. **Rimawi, M:** Breast Cancer Research Foundation Tbcrc 026 Amendment 1: A Phase 2 Clinical Trial Assessing The Correlation Of Early Changes In Standardized Uptake Value (Suv) On Positron Emission Tomography (Pet) With Pathological Complete Response (Pcr) To Pertuzumab And Trastuzumab In Patients With Primary Operable Her2-Positive Breast Cancer
32. **Rimawi, M:** Cascadian Therapeutics, Inc. 1 H-40306: Phase 2 Randomized, Double-Blinded, Controlled Study Of Ont-380 Vs. Placebo In Combination With Capecitabine And Ont-380-206: Trastuzumab In Patients With Pretreated Unresectable Locally Advanced Or Metastatic Her2+ Breast Carcinoma
33. **Rimawi, M:** Dana Farber Cancer Institute Tbcrc030: A Randomized Phase II Study Of Preoperative Cisplatin Versus Paclitaxel In Patients With Triple Negative Breast Cancer Without Germline Brca Mutations: Evaluating The Homologous Recombination Deficiency (Hrd) Biomarker
34. **Rimawi, M:** Galena Biopharma, Inc. Present: Prevention Of Recurrence In Early-Stage, Node-Positive Breast Cancer With Low To Intermediate Her2 Expression With Neuvax™ Treatment
35. **Rimawi, M:** Genentech Foundation For Growth & Dev A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Of Gdc-0941 Or Gdc-0980 With Fulvestrant Versus Fulvestrant In Advanced Or Metastatic Breast Cancer In Patients Resistant To

- Aromatase Inhibitor Therapy
36. **Rimawi, M:** Genentech, Inc. Pertain / Protocol Number Mo27775 / Ro43-68451 Pertuzumab
  37. **Rimawi, M:** Gilead Sciences, Inc. H-39960: Gsus3501937 A Phase 1B Study Followed By An Open Label, Parallel, Randomized Phase 2 Study Evaluating The Safety, Tolerability And Efficacy Of Gs-5829 In Combination With Exemestane Or Fulvestrant Comparing With Exemestane Or Fulvestrant Alone In Subjects With Advanced Estrogen Receptor Positive Her2- Breast Cancer
  38. **Rimawi, M:** Glaxo/Smithkline A Phase II Trial Of Lapatinib And Trastuzumab With Or Without Endocrine Therapy In Locally Advanced Her2 Overexpressing Breast Cancer Patients
  39. **Rimawi, M:** Glaxo/Smithkline Neoadjuvant Study Of Extended Lapatinib And Trastuzumab With Or Without Endocrine Therapy In Locally Advanced Her2- Overexpressing Breast Cancer Patients
  40. **Rimawi, M:** Novartis Pharmaceuticals Corp “A Randomized Phase III, Double-Blind, Placebo-Controlled, Multicenter Trial Of Daily Everolimus In Combination With Trastuzumab And Vinorelbine In Pretreated Women With Her2/Neu Over-Expressing Locally Advanced Or Metastatic Breast Cancer.”
  41. **Rimawi, M:** Novartis Pharmaceuticals Corp H 36350: Lee011: A Phase III Randomized, Double-Blind, Placebo-Controlled Study Of Lee011 Or Placebo In Combination With Tamoxifen And Goserelin Or A Non-Steroidal Aromatase Inhibitor (Nsai) / Clee011E2301 (Monaleesa-7) And Goserelin For The Treatment Of Premenopausal Women With Hormone Receptor Positive, Her2-Negative, Advanced Breast Cancer
  42. **Rimawi, M:** Pfizer, Inc Crizotinib And Sunitinib\_ A Rationally Combined Targeted Therapy Strategy For Metastatic Triple Negative Breast Cancer
  43. **Rimawi, M:** Pfizer, Inc Nsabb Fb-11: A Phase II Randomized Study Evaluating The Biological And Clinical Effects Of The Combination Of Palbociclib With Letrozole As Neoadjuvant Therapy In Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
  44. **Rimawi, M:** Pfizer, Inc H-39113 Nsabb Protocol B-57-I: Pallas: Palbociclib Collaborative Adjuvant Study:A Randomized Phase Iii Trial Of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone For Hormone Receptor Positive (Hr+) / Human Epidermal Growth Factor Receptor 2 (Her2)-Negative Early Breast Cancer
  45. **Rimawi, M:** Synthron Biopharmaceuticals, B.V. H-41823: A Multi-Centre, Open-Label, Randomized Clinical Trial Comparing The Efficacy And Safety Of The Antibody-Drug Conjugate Syd985 To Physician'S Choice In Patients With Her2-Positive Unresectable Locally Advanced Or Metastatic Breast Cancer
  46. **Sada, Y:** Merck & Co, Inc. Keynote-224: A Phase II Study Of Pembrolizumab (Mk-3475) As Monotherapy In Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma
  47. **Smaglio, B:** Mitra Biotech A Prospective, Multicenter, Observational Study Examining The Clinical Utility Of Canscripttm In Routine Clinical Practice
  48. **Zhang, J:** Advaxis Window-Of Opportunity Trial Of Neoadjuvant Adxs11-001 Vaccination Prior To Transoral Resection Of Hpv-Positive Oropharyngeal Squamous Cell Carcinoma
  49. **Zhang, J:** Astrazeneca A Phase III, Randomized, Multicenter, Open-Label, Comparative Study To Determine The Efficacy Of Durvalumab Or Durvalumab And Tremelimumab In Combination With Platinum-Based Chemotherapy For The First-Line Treatment In Patients With Extensive Disease (Stage Iv) Small-Cell Lung Cancer (Sclc)

50. **Zhang, J:** Regeneron Pharmaceuticals, Inc 1 A First-In-Human Study Of Repeat Dosing With Regn2810, A Monoclonal, Fully Human Antibody To Programmed Death – 1 (Pd-1), As Single Therapy And In Combination With Other Anti-Cancer Therapies, In Patients With Advanced Malignancies